NCT06782971Recruiting
Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
COSMOS-Avatar: Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX
Source: ClinicalTrials.gov · Last updated 8 Dec 2025
Brief summary (registry, in English)
The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived? Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 25 (estimated)
- First submitted
- 9 Jan 2025
- Start date
- Jun 2025
- Primary completion date
- Feb 2028
- Lead sponsor
- Clinical Hub for Interventional Research (CHOIR)
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06782971
What you commit to
- Study type: Observational
- Planned participants: 25
- From Jun 2025 to the primary completion date, Feb 2028
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- 1\. Presence of any condition that, by assessment of the Investigator, would compromise the safety of the patient if they participated, the quality of trial data, or their adherence to the study-specified procedures.
Who the study is looking for
- Age 18 years and above
- Patients with suspicion of AML requiring screening procedures
- Documented diagnosis of AML by WHO Classification and/or International Consensus Classification.
- Regardless of the number and type of prior lines of therapy or eligibility for allogeneic stem cell transplantation.
- All AML subtypes are eligible.
- Concurrent participation in clinical trials is allowed.
- Documented myeloblast percentage ≥20% in the bone marrow or peripheral blood within 12 weeks of C1D1 confirmed by bone marrow aspirate or peripheral blood smear.
- Planned to commence venetoclax and azacitidine therapy.
- Provision of written informed consent prior to any study-related assessments or procedures being carried out.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Canberra Health Services Coordinator of this site? Confirm its status | Canberra | Australia | Recruiting |
| Prince of Wales Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Recruiting |
| Royal North Shore Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Not yet recruiting |
| Westmead Hospital Coordinator of this site? Confirm its status | Westmead | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.